The Filing Desk

Mirum Pharmaceuticals vs Travere Therapeutics

Mirum Pharmaceuticals MIRM · Travere Therapeutics TVTX · Pharmaceuticals

Mirum Pharmaceuticals reported revenue of $521 million in fiscal 2025, about the same as Travere Therapeutics' $491 million in fiscal 2025. Mirum Pharmaceuticals' revenue grew 54.7% in its latest year, and Travere Therapeutics' grew 110.5%. Mirum Pharmaceuticals had an operating margin of -4.2%, against -12.8% at Travere Therapeutics.

Side by side

Mirum PharmaceuticalsTravere Therapeutics
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$521M$491M
Revenue growth54.7%110.5%
Revenue growth a year, last 5 years—19.9%
Gross margin—97.9%
Operating margin−4.2%−12.8%
Net margin−4.5%−5.2%
Free cash flow$55M—
Free cash flow margin10.5%—
Return on capital−7.1%—
Net debt to EBITDA−34.9x—
Dividends and buybacks$0M$0M
Change in diluted share count5.6%13.1%
Last close$93.99$50.65
P/E at the last close——
Insider trades, last 12 monthsbought $9.0 million, sold $42.9 millionsold $95.9 million
Piotroski F-score5 of 87 of 9
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Mirum PharmaceuticalsTravere Therapeutics
Operating margin
Percent of revenue
Mirum PharmaceuticalsTravere Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Mirum PharmaceuticalsTravere Therapeutics

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Mirum Pharmaceuticals and Travere Therapeutics pages.